Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 4/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.41 |
| ▸ | HTR3B | O95264 | 3/20 | 0.41 |
| ▸ | HTR3A | P46098 | 3/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30014583 | 1.00 | NAMPT (0.50) | NAMPTCYP3A4KMT2AMYCFYN | |
| SCHEMBL23535506 | 0.90 | CYP3A4 (0.59) | NAMPTCYP3A4KMT2AMYCFYN | |
| SCHEMBL23535518 | 0.84 | FYN (0.45) | FYN | |
| SCHEMBL23535523 | 0.84 | FYN (0.49) | FYN | |
| SCHEMBL23535507 | 0.84 | FYN (0.48) | FYN | |
| SCHEMBL23535535 | 0.83 | HPGD (0.47) | FYN | |
| SCHEMBL23535526 | 0.79 | POLB (0.55) | NAMPTKMT2AMEN1 | |
| SCHEMBL30014341 | 0.79 | POLB (0.55) | NAMPTKMT2AMEN1 | |
| SCHEMBL23547226 | 0.78 | FYN (0.43) | FYN | |
| SCHEMBL23535536 | 0.77 | HPGDS (0.49) | KMT2AFYNMAPK14MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230056497-A1 | CD206 Modulators Their Use and Methods for Preparation | US HEALTH (US) | 2023-02-23 | — | — | US | disclosed |
| WO-2021126923-A1 | CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126923-A1 | CD206 MODULATORS THEIR USE AND METHODS FOR PREPARATION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056497-A1 | CD206 Modulators Their Use and Methods for Preparation | CD209, MSR1, ARG1 | NAMPT 2002/4885CYP3A4 1486/4885KMT2A 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.